ArticleLiver international : official journal of the International Association for the Study of the Liver2021

Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.

Aldo Prawira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.